Advertisement

Tumor Biology

, Volume 36, Issue 3, pp 1903–1911 | Cite as

Downregulation of miR-25 modulates non-small cell lung cancer cells by targeting CDC42

  • Tian Yang
  • Tianjun Chen
  • Yang Li
  • Lei Gao
  • Shuo Zhang
  • Ting Wang
  • Mingwei Chen
Research Article

Abstract

The current study aims to investigate the fuctional role of miRNA-25 in non-small cell lung cancer (NSCLC) cells. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of miR-25 in NSCLC cell lines and 11 pairs of human NSCLC and non-cancerous tissues. The inhibitor of miR-25 was stably transfected into NSCLC cell line A549 cells. Then the effects of downregulating miR-25 on cancer cell proliferation, cell cycle arrest, chemosensitivity to cisplatin, and growth of in vivo xenograft were investigated. Direct regulation of miR-25 on its target gene, cell division cycle 42 (CDC42), was examined by luciferase reporter assay, qRT-PCR and western blot. CDC42 was then upregulated in A549 cells to investigate its effect on miR-25-mediated NSCLC cell proliferation and cell cycle arrest. The expression of miR-25 in NSCLC cells or human tissues was significantly higher than that in normal lung cells or adjacent non-cancerous tissues, respectively. Downregulation of miR-25 markedly inhibited A549 cell proliferation, induced G1 cell cycle arrest, increased cisplatin sensitivity, and suppressed the growth of caner cell xenograft in vivo. CDC42 was confirmed to be the directly regulated by miR-25 in A549 cells. Upregulation of CDC42 in A549 cells rescued the inhibitory effect on proliferation and the G1 cell cycle arrest induced by miR-25 downregulation. Our study demonstrates miR-25, by targeting CDC42, is an important regulator in NSCLC.

Keywords

NSCLC A549 Mir-25 CDC42 

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: A Cancer J Clin. 2012;62:10–29.Google Scholar
  2. 2.
    Rivera MP. Multimodality therapy in the treatment of lung cancer. Semin Respir Crit Care Med. 2004;25 Suppl 1:3–10.CrossRefPubMedGoogle Scholar
  3. 3.
    Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.CrossRefPubMedGoogle Scholar
  4. 4.
    Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA? RNA. 2005;11:1753–61.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007;39:673–7.CrossRefPubMedGoogle Scholar
  6. 6.
    He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435:828–33.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006;94:776–80.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167–79.CrossRefPubMedGoogle Scholar
  9. 9.
    Lynam-Lennon N, Maher SG, Reynolds JV. The roles of microRNA in cancer and apoptosis. Biol Rev Camb Philos Soc. 2009;84:55–71.CrossRefPubMedGoogle Scholar
  10. 10.
    Wang Y, Lee CG. MicroRNA and cancer—focus on apoptosis. J Cell Mol Med. 2009;13:12–23.CrossRefPubMedGoogle Scholar
  11. 11.
    Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther. 2010;17:523–31.CrossRefPubMedGoogle Scholar
  12. 12.
    Nordentoft I, Birkenkamp-Demtroder K, Agerbaek M, Theodorescu D, Ostenfeld MS, Hartmann A, et al. MiRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genet. 2012;5:40.Google Scholar
  13. 13.
    Singh S, Chitkara D, Kumar V, Behrman SW, Mahato RI. MiRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett. 2013;334:211–20.CrossRefPubMedGoogle Scholar
  14. 14.
    Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, et al. MiRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genet. 2011;4:79.Google Scholar
  15. 15.
    Zhang H, Zuo Z, Lu X, Wang L, Wang H, Zhu Z. MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep. 2012;27:594–8.PubMedGoogle Scholar
  16. 16.
    Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan AC, et al. The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene. 2012;31:5162–71.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, et al. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci. 2009;100:1234–42.CrossRefPubMedGoogle Scholar
  18. 18.
    Tan W, Li Y, Lim SG, Tan TM. MiR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. World J Gastroenterol: WJG. 2014;20:5962–72.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.CrossRefPubMedGoogle Scholar
  20. 20.
    Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res: off J Am Assoc Cancer Res. 2010;16:430–41.CrossRefGoogle Scholar
  21. 21.
    Arias-Romero LE, Chernoff J. Targeting Cdc42 in cancer. Expert Opin Ther Targets. 2013;17:1263–73.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Stengel K, Zheng Y. Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell Signal. 2011;23:1415–23.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Zhang JY, Zhang D, Wang EH. Overexpression of small GTPases directly correlates with expression of delta-catenin and their coexpression predicts a poor clinical outcome in nonsmall cell lung cancer. Mol Carcinog. 2013;52:338–47.CrossRefPubMedGoogle Scholar
  24. 24.
    Hua KT, Tan CT, Johansson G, Lee JM, Yang PW, Lu HY, et al. N-alpha-acetyltransferase 10 protein suppresses cancer cell metastasis by binding PIX proteins and inhibiting Cdc42/Rac1 activity. Cancer Cell. 2011;19:218–31.CrossRefPubMedGoogle Scholar
  25. 25.
    Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 1995;269:1270–2.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Tian Yang
    • 1
  • Tianjun Chen
    • 1
  • Yang Li
    • 1
  • Lei Gao
    • 1
  • Shuo Zhang
    • 1
  • Ting Wang
    • 1
  • Mingwei Chen
    • 1
  1. 1.Department of Respiratory Medicine, The First Affiliated Hospital, College of MedicineXi’an Jiaotong UniversityXi’anChina

Personalised recommendations